Daily Amino Acid Supplementation for People With Parkinson's Disease

Part of paid clinical trials in Storrs, Connecticut.

Sponsor
Cristina Colon-Semenza
Study ID
NCT07115563
Status
Recruiting
Apply to this trial

Conditions

  • Parkinson Disease (PD)

Eligibility Criteria

Sex
ALL
Age
60 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Targeted Amino Acid Supplement — DIETARY_SUPPLEMENT
    Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
  • Control (placebo) — DIETARY_SUPPLEMENT
    The inert amino acid (alanine) will serve as an isonitrogenous control.

Study Details

The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid supplement increase essential amino acids (nutritional status)? Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress? Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement? Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease. Participants will: Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.

Key Dates

Start date
Oct 31, 2025
Status verified
Nov 2025
Primary completion
Sep 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Placebo Comparator: Control
    The inert amino acid (alanine) will serve as an isonitrogenous control.
  • Experimental: Targeted Amino Acid Supplement
    Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).

Primary Outcome Measure

Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione) [ Time Frame: Baseline, 3 months, and 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ConnecticutStorrsConnecticut06269
Jacob Earp, MS
[email protected]
860-486-2671
Carlos Rehbein
[email protected]
Jacob Earp, PhD (PRINCIPAL_INVESTIGATOR)
Cristina Colon-Semenza, PT, MPT, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Storrs, CT

By research site
University of Connecticut· Storrs, CT

Related Studies